MTOR and breast carcinoma: We can speculate that linc‐ROR promotes breast cancer cells to survive in rapamycin treatment by functioning as a ceRNA sponge for miR‐194‐3p, removing its inhibitory effect on MECP2 and downregulating the expression level of mTOR.